Brii Biosciences Launches Amubarvimab/Romlusevimab Combination in China for the Treatment of COVID-19
Shots:
- Brii Bio launched amubarvimab + romlusevimab in China as a long-acting COVID-19 neutralizing Ab therapy based on the approval granted by NMPA in Dec’21 for the treatment of adults/pediatric patients (aged 12-17yrs, 40kg) with mild/normal COVID-19
- The approval was based on the P-III (ACTIV-2) trial evaluating amubarvimab + romlusevimab vs PBO in 837 patients with results demonstrating an 80% reduction in hospitalization/death @28days & improved safety
- Amubarvimab and romlusevimab are non-competing SARS-CoV-2 neutralizing mAb extracted from the recovered COVID-19 patients. This combination therapy was jointly developed by Brii Bio, the 3rd People's Hospital of Shenzhen & Tsinghua University
Ref: PRNewswire | Image: Brii Biosciences
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
